Efficacy and safety of the angiotensin II receptor blocker losartan for hypertrophic cardiomyopathy: the INHERIT randomised, double-blind, placebo-controlled trial

Maron, 1995, Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults, Circulation, 92, 785, 10.1161/01.CIR.92.4.785 Konno, 2010, Genetics of hypertrophic cardiomyopathy, Curr Opin Cardiol, 25, 205, 10.1097/HCO.0b013e3283375698 Andersen, 2009, Diagnostic yield, interpretation, and clinical utility of mutation screening of sarcomere encoding genes in Danish hypertrophic cardiomyopathy patients and relatives, Hum Mutat, 30, 363, 10.1002/humu.20862 Morita, 2008, Shared genetic causes of cardiac hypertrophy in children and adults, N Engl J Med, 358, 1899, 10.1056/NEJMoa075463 Olivotto, 2008, Myofilament protein gene mutation screening and outcome of patients with hypertrophic cardiomyopathy, Mayo Clin Proc, 83, 630, 10.1016/S0025-6196(11)60890-2 Force, 2010, Research priorities in hypertrophic cardiomyopathy: report of a Working Group of the National Heart, Lung, and Blood Institute, Circulation, 122, 1130, 10.1161/CIRCULATIONAHA.110.950089 Shimada, 2013, Effects of losartan on left ventricular hypertrophy and fibrosis in patients with nonobstructive hypertrophic cardiomyopathy, JACC Heart Fail, 1, 480, 10.1016/j.jchf.2013.09.001 American College of Cardiology Foundation/American Heart Association Task Force on Practice, 2011, 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, J Thorac Cardiovasc Surg, 142, e153, 10.1016/j.jtcvs.2011.10.020 Cannan, 1995, Natural history of hypertrophic cardiomyopathy. A population-based study, 1976 through 1990, Circulation, 92, 2488, 10.1161/01.CIR.92.9.2488 Spirito, 1989, Clinical course and prognosis of hypertrophic cardiomyopathy in an outpatient population, N Engl J Med, 320, 749, 10.1056/NEJM198903233201201 Cecchi, 1995, Hypertrophic cardiomyopathy in Tuscany: clinical course and outcome in an unselected regional population, J Am Coll Cardiol, 26, 1529, 10.1016/0735-1097(95)00353-3 Maron, 2003, Clinical course of hypertrophic cardiomyopathy with survival to advanced age, J Am Coll Cardiol, 42, 882, 10.1016/S0735-1097(03)00855-6 Devereux, 2004, Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial, Circulation, 110, 1456, 10.1161/01.CIR.0000141573.44737.5A Teekakirikul, 2010, Cardiac fibrosis in mice with hypertrophic cardiomyopathy is mediated by non-myocyte proliferation and requires Tgf-β, J Clin Invest, 120, 3520, 10.1172/JCI42028 Lim, 2001, Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy, Circulation, 103, 789, 10.1161/01.CIR.103.6.789 Tsybouleva, 2004, Aldosterone, through novel signaling proteins, is a fundamental molecular bridge between the genetic defect and the cardiac phenotype of hypertrophic cardiomyopathy, Circulation, 109, 1284, 10.1161/01.CIR.0000121426.43044.2B de Resende, 2006, Combined effects of low-dose spironolactone and captopril therapy in a rat model of genetic hypertrophic cardiomyopathy, J Cardiovasc Pharmacol, 48, 265, 10.1097/01.fjc.0000248236.43760.86 Penicka, 2009, The effects of candesartan on left ventricular hypertrophy and function in nonobstructive hypertrophic cardiomyopathy: a pilot, randomized study, J Mol Diagn, 11, 35, 10.2353/jmoldx.2009.080082 Kawano, 2005, Valsartan decreases type I collagen synthesis in patients with hypertrophic cardiomyopathy, Circ J, 69, 1244, 10.1253/circj.69.1244 Yamazaki, 2007, A new therapeutic strategy for hypertrophic nonobstructive cardiomyopathy in humans. A randomized and prospective study with an angiotensin II receptor blocker, Int Heart J, 48, 715, 10.1536/ihj.48.715 Araujo, 2005, Effect of losartan on left ventricular diastolic function in patients with nonobstructive hypertrophic cardiomyopathy, Am J Cardiol, 96, 1563, 10.1016/j.amjcard.2005.07.065 Lang, 2005, J Am Soc Echocardiogr, 18, 1440, 10.1016/j.echo.2005.10.005 Jensen, 2013, Penetrance of hypertrophic cardiomyopathy in children and adolescents: a 12-year follow-up study of clinical screening and predictive genetic testing, Circulation, 127, 48, 10.1161/CIRCULATIONAHA.111.090514 Spoladore, 2012, Pharmacological treatment options for hypertrophic cardiomyopathy: high time for evidence, Eur Heart J, 33, 1724, 10.1093/eurheartj/ehs150 Hall, 2005, NT-ProBNP: the mechanism behind the marker, J Card Fail, 11, S81, 10.1016/j.cardfail.2005.04.019 Thaman, 2006, Usefulness of N-terminal pro-B-type natriuretic peptide levels to predict exercise capacity in hypertrophic cardiomyopathy, Am J Cardiol, 98, 515, 10.1016/j.amjcard.2006.02.057 Saura, 2009, Left atrial remodelling in hypertrophic cardiomyopathy: relation with exercise capacity and biochemical markers of tissue strain and remodelling, Int J Clin Pract, 63, 1465, 10.1111/j.1742-1241.2009.02127.x Todiere, 2012, Progression of myocardial fibrosis assessed with cardiac magnetic resonance in hypertrophic cardiomyopathy, J Am Coll Cardiol, 60, 922, 10.1016/j.jacc.2012.03.076 Guttmann, 2014, Atrial fibrillation and thromboembolism in patients with hypertrophic cardiomyopathy: systematic review, Heart, 100, 465, 10.1136/heartjnl-2013-304276 Ho, 2013, T1 measurements identify extracellular volume expansion in hypertrophic cardiomyopathy sarcomere mutation carriers with and without left ventricular hypertrophy, Circ Cardiovasc Imaging, 6, 415, 10.1161/CIRCIMAGING.112.000333 Dalsgaard, 2014, Short-term hemodynamic effect of angiotensin-converting enzyme inhibition in patients with severe aortic stenosis: a placebo-controlled, randomized study, Am Heart J, 167, 226, 10.1016/j.ahj.2013.11.002 Green, 2012, Prognostic value of late gadolinium enhancement in clinical outcomes for hypertrophic cardiomyopathy, JACC Cardiovasc Imaging, 5, 370, 10.1016/j.jcmg.2011.11.021 O'Mahony, 2014, A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM Risk-SCD), Eur Heart J, 35, 2010, 10.1093/eurheartj/eht439 Spirito, 2000, Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy, N Engl J Med, 342, 1778, 10.1056/NEJM200006153422403 Olivotto, 2008, Assessment and significance of left ventricular mass by cardiovascular magnetic resonance in hypertrophic cardiomyopathy, J Am Coll Cardiol, 52, 559, 10.1016/j.jacc.2008.04.047